PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway

Although preclinical work with rapalogs suggests potential in the treatment of gastric cancer, they have been less successful clinically. In this study, we report the impact of the investigational drug PP242, a potent and selective small-molecule active-site TORC1/2 kinase inhibitor, on tumor growth...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Anticancer Drugs
Auteurs principaux: Xing, Xiaofang, Zhang, Lianhai, Wen, Xianzi, Wang, Xiaohong, Cheng, Xiaojing, Du, Hong, Hu, Ying, Li, Lin, Dong, Bin, Li, Ziyu, Ji, Jiafu
Format: Artigo
Langue:Inglês
Publié: Lippincott Williams & Wilkins 2014
Sujets:
Preclinical Reports
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4222793/
https://ncbi.nlm.nih.gov/pubmed/25035961
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CAD.0000000000000148
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires